Landos Biopharma:
Lanthionine Synthetase C-Like 2 (LANCL2) is a novel therapeutic target for autoimmune diseases, including inflammatory bowel disease (IBD); Crohn’s disease (CD) and ulcerative colitis (UC). Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile. Successfully raised $60MM Series B in August 2019 with Perceptive and RTW.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - South Atlantic
Clinical Stage
Phase l or ll
Disease Space
Autoimmune
Listing
Private
Website:
Profiles:
Address:
1800 Kraft Drive SW
Suite 216
Blacksburg, VA 24060
United States
Suite 216
Blacksburg, VA 24060
United States
Company Participants at Solebury Trout Management Access SF 2020
- Josep Bassaganya-Riera, President & CEO
- Jyoti Chauhan
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Summer 2020 NYC Private Company Showcase
New York, NY,
August 10, 2020
Lead Programs
BT-11
| Indication | Phase |
|---|---|
| LANCL2 | 2 |
| LANCL2 | 1 |
NX-13
| Indication | Phase |
|---|---|
| NLRX1 | IND |
| NLRX1 | IND |
BT-104
| Indication | Phase |
|---|---|
| LANCL2 | Pre-clinical |
| LANCL2 | Pre-clinical |